Fecal M2-pyruvate kinase (M2-PK): A novel marker of intestinal inflammation

Inflammatory Bowel Diseases

Volumn 13, Issue 11, 2007, Pages 1374-1378

  Chung Faye, Guy ^a   Hayee, Bu'Hussain ^a   Maestranzi, Susan ^a   Donaldson, Nora ^a   Forgacs, Ian ^a   Sherwood, Roy ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Calprotectin; Colorectal cancer; Crohn's disease; Inflammatory bowel disease; Irritable bowel syndrome; M2 pyruvate kinase; Ulcerative colitis

Indexed keywords

CALPROTECTIN; PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FECES ANALYSIS; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CROHN DISEASE; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL DISEASES; IRRITABLE BOWEL SYNDROME; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PYRUVATE KINASE;

EID: 36749059545     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20214     Document Type: Article

References (20)

1. The role of colonoscopy in the management of patients with inflammatory bowel disease. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc. 1998;48:689-690.
2. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation to distinguish organic from non-organic intestinal disease. Gastroenterology. 2002;123:450-460.
3. Pardi S, Sandborn WJ. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? Gut. 2005;54:321-322.
4. Mazurek S, Grimm H, Oehmke M, et al. Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumour cells. Anticancer Res. 2000;20:5151-5154.
5. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, et al. Double role for pyruvate kinase type M2 in expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncogen. 1992;3:91-115.
6. Ibsen KH, Orlando RA, Garrat KN, et al. Expression of multimolecular forms of pyruvate kinase in normal, benign and malignant human breast tissue. Cancer Res. 1982;42:888-892.
7. Schulze G. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. Anticancer Res. 2000;20:4961-6964.
8. Hardt PD, Ngoumou BK, Rupp J, et al. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastrointestinal cancer. Anticancer Res. 2000;20:4965-4968.
9. Sipos F, Molnar B, Zagoni T, et al. Growth in epithelial cell proliferation and apoptosis correlates specifically to the inflammation activity of inflammatory bowel diseases: ulcerative colitis shows specific p53- and EGFR expression alterations. Dis Colon Rectum. 2005;48:775-786.
10. Sherwood R, Maestranzi S, Forgacs I, et al. Fecal M2-pyruvate kinase: a novel, non-invasive marker of bowel inflammation. Clin Chim Acta. 2005;355:S157.
11. Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as demonstrated by a simple fecal test. Gut. 1999;45:362-366.
12. Sandborn WJ, Tremaine WJ, Schroeder KW, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology. 1994;106:1429-1435.
13. Rome II: A multinational consensus document on functional gastrointestinal disorders. Gut. 1999;45(Suppl 2):II1-II80.
14. Hugo F, Fischer G, Eigenbrodt E. Quantitative detection of tumor M2-PK in serum and plasma. Anticancer Res. 1999;19:2753-2758.
15. Hugo F, Mazurek S, Hardt PD, et al. Quantitative detection of Tumor M2-PK: Evaluation of blood and stool specimen stability. Poster WP18.39 at European Congress of Clinical Chemistry and Laboratory Medicine. 2005. Glasgow.http://www.schebo.com/onko/en/Literaturanforderungen%20englisch.pdf
16. Kane S, Sandborn W, Rufo P, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003;98:1309-1314.
17. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000;47:506-513.
18. Gaya DR, Lyon TD, Duncan A, et al. Fecal calprotectin in the assessment of Crohn's disease activity. Q J Med. 2005;98:435-441.
19. Pardi DS, Sandborn WJ. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? Gut. 2005;54:321-322.
20. Jones J, Boorman J, Cann P, et al. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. http://www.bsg.org.uk/guidelines